

Appendix 8: Pooled results for Mirena® v second generation endometrial destruction [posted as supplied by author]

	Time point	Trials (no.)	WMD (95%CI) \$	OR (95%CI) #	P-value	Hetero (p)/ I ² (%)
Proportion amenorrhoea	6 months	2 (107)	-	1.76 (0.42 to 7.34)	0.4	0.5/ 0
	12 months	3 (127)	-	2.43 (0.61 to 9.67)	0.2	0.02/ 82
	2 years	1 (39)	-	5.99 (1.43 to 25.1)	0.01	-
Proportion with heavy bleeding	6 months	3 (162)	-	4.30 (1.76 to 10.6)	0.001	0.6/ 0
	12 months	4 (200)	-	1.54 (0.56 to 4.24)	0.4	0.02/ 75
	2 years	1 (39)	-	13.0 (2.00 to 84.2)	0.007	-
Bleeding score (change)	6 months	4 (169)	10 (-37 to 57)	-	0.7	0.2/ 29
	12 months	4 (168)	-35 (-75 to 5)	-	0.09	0.3/ 26
	2 years	1 (39)	117 (-113 to 347)	-	0.7	-
Proportion dysmenorrhoea	6 months	1 (83)	-	0.78 (0.33 to 1.85)	0.6	-
	12 months	1 (48)	-	0.77 (0.25 to 2.43)	0.7	-
	2 years	1 (83)	-	0.97 (0.31 to 3.05)	1.0	-
SF36 General health (absolute)		3 (147)	3.7 (-2.7 to 10.1)	-	0.3	0.006/ 81
SF36 Physical function (absolute)		3 (146)	-0.9 (-6.9, 5.0)	-	0.8	0.6/ 0
SF36 Role physical (absolute)		3 (147)	-9.6 (-20.5, 1.3)	-	0.08	0.1/ 56
SF36 Role emotional (absolute)	12 months	3 (147)	5.7 (-5.4, 16.8)	-	0.3	0.02/ 75
SF36 Mental health (absolute)		3 (146)	-0.8 (-6.7 to 5.1)	-	0.8	0.02/ 73
SF36 Social function (absolute)		3 (147)	2.3 (-3.6 to 8.2)	-	0.4	0.06/ 65
SF36 Vitality (absolute)		3 (146)	0.08 (-5.9 to 6.1)	-	1.0	0.3/ 7
SF36 Pain (absolute)		3 (147)	1.1 (-6.6 to 8.9)	-	0.8	1.0/ 0
SF36 General health (absolute)		1 (49)	1.7 (-10.3 to 13.7)	-	0.8	-
SF36 Physical function (absolute)		1 (50)	-1.2 (-8.0 to 5.6)	-	0.7	-
SF36 Role physical (absolute)		1 (50)	8.2 (-4.9 to 21.3)	-	0.2	-
SF36 Role emotional (absolute)	2 years	1 (50)	-1.0 (-16.4 to 14.4)	-	0.9	-
SF36 Mental health (absolute)		1 (49)	-0.4 (-8.9 to 8.1)	-	0.9	-
SF36 Social function (absolute)		1 (50)	2.2 (-7.0 to 11.4)	-	0.6	-
SF36 Vitality (absolute)		1 (49)	1.8 (-8.6 to 12.2)	-	0.7	-
SF36 Pain (absolute)		1 (50)	8.7 (-2.3 to 19.7)	-	0.1	-
SF36 General health (change)		2 (81)	1.9 (-6.5 to 10.4)	-	0.7	0.1/ 59
SF36 Physical function (change)		2 (81)	-0.5 (-10.1 to 9.2)	-	0.9	0.5/ 0
SF36 Role physical (change)	12 months	2 (82)	-7.0 (-28.9 to 14.9)	-	0.5	0.8/ 0
SF36 Role emotional (change)		2 (82)	1.8 (-18.5 to 22.1)	-	0.9	0.04/ 75
SF36 Mental health (change)		2 (81)	-2.1 (-9.6 to 5.4)	-	0.6	0.03/ 78
SF36 Social function (change)		2 (82)	-1.9 (-10.9 to 7.1)	-	0.7	0.2/ 49
SF36 Vitality (change)		2 (80)	-2.0 (-12.2 to 8.2)	-	0.7	0.7/ 0
SF36 Pain (change)		2 (82)	-8.0 (-20.0 to 3.9)	-	0.2	0.6/ 0
SF36 General health (change)	2 years	1 (49)	-4.1 (-14.0 to 5.8)	-	0.4	-

SF36 Physical function (change)	1 (50)	-4.4 (-14.9 to 6.1)	-	0.4	-
SF36 Role physical (change)	1 (50)	-1.1 (-28.4 to 26.2)	-	0.9	-
SF36 Role emotional (change)	1 (50)	2.0 (-23.3 to 27.3)	-	0.9	-
SF36 Mental health (change)	1 (49)	-5.7 (-14.2 to 2.8)	-	0.2	-
SF36 Social function (change)	1 (50)	-4.9 (-17.6 to 7.8)	-	0.5	-
SF36 Vitality (change)	1 (49)	-9.6 (-20.4 to 1.2)	-	0.08	-
SF36 Pain (change)	1 (50)	1.3 (-17.8 to 15.2)	-	0.9	-
 Hysterectomy after endometrial destruction/Mirena	 6 months	1 (50)	 - 1.79 (0.40 to 8.01)	 0.5	 -
	12 months	2 (105)	- 0.22 (0.05 to 1.04)	0.06	0.9/ 0
	2 years	2 (146)	- 0.86 (0.33 to 0.21)	0.8	0.2/ 41
 Discontinued Mirena	 6 months	Trials 1	Freq 3/42 (7%)		
	12 months	3	18/96 (19%)		
	2 years	2	21/75 (28%)		
 Endometrial destruction after Mirena	 12 months	1	3/18 (17%)		
	2 years	1	4/42 (10%)		
	6 months	1	3/25 (12%)		
 Hysterectomy after Mirena	 12 months	2	6/54 (11%)		
	2 years	2	11/75 (15%)		

Peri-procedure complications:	Trials	Freq (2 nd Gen: max 158, Mirena: max 157)	OR (95%CI) #	P-value	Hetero (p)/ I ² (%)
- Uterine perforation (2 nd gen, Mirena)	5	0, 0	-	-	-
- Cervical laceration (2 nd gen, Mirena)	5	0, 0	-	-	-
- Anaesthesia problems (2 nd gen)	5	0	-	-	-
- Excessive bleeding (2 nd gen)	5	0	-	-	-
- Fluid overload (2 nd gen)	5	0	-	-	-
- Visceral damage (2 nd gen)	5	0	-	-	-
- Procedure abandoned (2 nd gen)	5	0	-	-	-
- Converted to hysterectomy (2 nd gen)	5	0	-	-	-
- Failed to insert (Mirena)	5	0	-	-	-
Further complications (<1 month):					
- Urinary tract infection (2 nd gen)	5	0	-	-	-
- DVT (2 nd gen)	5	0	-	-	-
- Further bleeding (2 nd gen)	5	0	-	-	-
- Sepsis (2 nd gen)	5	0	-	-	-
- Pyrexia (2 nd gen)	5	0	-	-	-
- Endometriosis (2 nd gen)	5	0	-	-	-
- Haematomata (2 nd gen)	5	0	-	-	-
- Abdominal pain (2 nd gen)	5	0	-	-	-
- Foul discharge (2 nd gen)	5	0	-	-	-
- Visceral damage (2 nd gen)	5	0	-	-	-
- Infection (Mirena)	5	0	-	-	-
- Expelled/migrated (Mirena)	5	5	-	-	-
- Removed before 3 months (Mirena)	5	4	-	-	-

$\$ <0$ Favours second generation endometrial destruction, ≥ 0 Mirena®

[#]<1 Favours second generation endometrial destruction, >1 Mirena®